LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

LLY

1,162.5

+0.3%↑

JNJ

239.94

+2.35%↑

ABBV

226.77

+0.29%↑

UNH

407.54

-1.09%↓

MRK

118.88

-0.59%↓

Home・Lista de Ações・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Abrir

SetorSaúde

21.45

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Indicadores-chave
By Trading Economics
Rendimento	-1.6M -21M
Vendas	14M 54M
Margem de lucro	-39.611
Funcionários	178
EBITDA	-7.7M -26M

Recomendações
By TipRanks
Recomendações	Neutro
Previsão para 12 meses	-3.62% downside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	1B 2.2B
Abertura anterior	21.45
Fecho anterior	21.45

Sentimento de Notícias

By Acuity

50%

153 / 344 Ranking em Healthcare

Day One Biopharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de jun. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 de jun. de 2026, 23:45 UTC

Aquisições, Fusões, Aquisições de Empresas

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 de jun. de 2026, 23:44 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 de jun. de 2026, 23:43 UTC

Aquisições, Fusões, Aquisições de Empresas

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 de jun. de 2026, 23:35 UTC

Conversa de Mercado

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 de jun. de 2026, 22:06 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 de jun. de 2026, 22:05 UTC

Aquisições, Fusões, Aquisições de Empresas

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 de jun. de 2026, 20:51 UTC

Ganhos

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 20:09 UTC

Conversa de Mercado

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 de jun. de 2026, 19:36 UTC

Conversa de Mercado

Cattle Climbs as Crude Oil Falls -- Market Talk

9 de jun. de 2026, 19:32 UTC

Conversa de Mercado

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 de jun. de 2026, 19:25 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 de jun. de 2026, 19:00 UTC

Conversa de Mercado

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 de jun. de 2026, 18:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 de jun. de 2026, 18:47 UTC

Conversa de Mercado

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 de jun. de 2026, 18:37 UTC

Conversa de Mercado

Canada's Cooling Trade With the U.S. -- Market Talk

9 de jun. de 2026, 18:27 UTC

Conversa de Mercado

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 de jun. de 2026, 17:35 UTC

Conversa de Mercado

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 de jun. de 2026, 17:30 UTC

Conversa de Mercado

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 de jun. de 2026, 16:34 UTC

Conversa de Mercado

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

9 de jun. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Health Care Roundup: Market Talk

9 de jun. de 2026, 15:28 UTC

Conversa de Mercado

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 de jun. de 2026, 15:25 UTC

Conversa de Mercado

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Comparação entre Pares

Variação de preço

Day One Biopharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

-3.62% parte inferior

Previsão para 12 meses

Média 20.75 USD -3.62%

Máximo 21.5 USD

Mínimo 17 USD

Com base em 7 analistas de Wall Street que oferecem metas de preço de 12 meses para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

7 ratings

Comprar

Manter

Vender

Com base em 7 analistas que deram avaliações de ações para Day One Biopharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

153 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.